← All trials
NCT02161757
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2014
- Primary completion
- Feb 28, 2017
- Completion date
- Jul 14, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 2247
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- University of PennsylvaniaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.